PRP/Cell-Based/Osteoinductive Materials

September 7, 2021

Locate Bio Closes £10 Million Funding Round

Locate Bio Closes £10 Million Funding Round
Proceeds will further advance the company's regenerative medicine pipeline of orthobiologic products.
August 17, 2021

Royal Biologics Partners with Vilex for Lower Extremities

Royal Biologics Partners with Vilex for Lower Extremities
Vilex will market and distribute Royal Biologics' portfolio of Autologous and Live Cellular therapies for lower extremity orthopedic procedures.
May 10, 2021

Puregraft Fat Used to Treat Knee Osteoarthritis

Puregraft Fat Used to Treat Knee Osteoarthritis
Studies indicate that Puregraft fat grafting significantly improved function and symptom relief at 3 and 6 months in patients with knee OA.
April 27, 2021

DiscGenics Study Updates: Injectable Discogenic Cell Therapy

DiscGenics Study Updates: Injectable Discogenic Cell Therapy
The company has completed enrollment in its Japanese safety study of allogeneic, injectable discogenic cell therapy for lumbar disc degeneration.
February 17, 2021

Signature Cord Prime Phase 1 Study for Knee OA

Signature Cord Prime Phase 1 Study for Knee OA
FDA approved an IND Application to study Signature Cord Prime in patients with symptomatic osteoarthritis of the knee.
January 20, 2021

FDA Clinical Hold for Histogen Trial in Knee Regeneration

FDA Clinical Hold for Histogen Trial in Knee Regeneration
FDA verbally notified the company of additional questions in the application for the planned Phase I/II trial of HST-003 combined with microfracture.
January 12, 2021

Bone Therapeutics Kicks Off ALLOB Tibial Fracture Study

Bone Therapeutics Kicks Off ALLOB Tibial Fracture Study
ALLOB will be applied by a single injection up to 4 days post-reduction surgery in patients with fresh tibial fractures at risk for delayed or non-union.
December 29, 2020

Fuse Medical Launches FuseChoice Biologics Portfolio

Fuse Medical Launches FuseChoice Biologics Portfolio
In 1H21, the company will launch FusePure Demineralized Bone Matrix, Strips and Cubes, and FuseTrilogy Viable Bone Matrix.
October 14, 2020

ALLOB Shows 90% Fusion Rate at 2 Years in Phase IIa Study

ALLOB Shows 90% Fusion Rate at 2 Years in Phase IIa Study
90% of patients show bone fusion as well as strong clinical improvements in function and pain at 24 months follow-up with a good product safety profile.
October 5, 2020

Bone Therapeutics Collaborates on ALLOB in Asia

Bone Therapeutics Collaborates on ALLOB in Asia
Bone Therapeutics granted an exclusive license to develop and collaborate on ALLOB in Greater China and a number of other major Asian countries.
August 25, 2020

DiscGenics Raises $50 Million in Series C Funding

DiscGenics Raises $50 Million in Series C Funding
The company will use the capital to support ongoing clinical trials of its injectable Discogenic Cell Therapy (IDCT) for lumbar degenerative disc disease.
August 11, 2020

Vericel Expects Growth in Second Half 2020

Vericel Expects Growth in Second Half 2020
The company exited 2Q20 with significant momentum in June and expects MACI to grow at least in the mid-single-digits for the second half of the year.

Member-Only Content

April 7, 2020

InGeneron Cell Therapy in Rotator Cuff Repair – Study Results

InGeneron Cell Therapy in Rotator Cuff Repair – Study Results
InGeneron announces favorable study results using regenerative autologous adipose-derived cells that are prepared with the Transpose® RT System for treatment of partial-thickness rotator cuff tears.
March 18, 2020

Orthobiologics Face Pressure from Lack of Clinical Evidence

Orthobiologics Face Pressure from Lack of Clinical Evidence
In the race to capitalize on patient-driven interest in stem cells, biologic solutions and “regeneration” of a more vital, healthy and functional body, there has been an explosion of offerings that lack scientific controls, validity and meaningful evidence.
January 21, 2020

Anika Therapeutics Takes Major Step in Strategic Transformation with Acquisition of Parcus Medical and Arthrosurface

Anika Therapeutics Takes Major Step in Strategic Transformation with Acquisition of Parcus Medical and Arthrosurface
With the acquisitions of Parcus Medical and Arthrosurface, Anika looks ready to complete a major step in its five-year strategic plan to become a leader in joint preservation and restoration.

Member-Only Content

November 18, 2019

Cerapedics Gains FDA Approval of PMA Supplement for i-FACTOR

Cerapedics Gains FDA Approval of PMA Supplement for i-FACTOR
FDA approved Cerapedics' Premarket Approval supplement for i-FACTOR® Peptide Enhanced Bone Graft for use in ACDF to treat degenerative cervical disc disease.
November 14, 2019

Personalized Stem Cells Clinical Trial Update

Personalized Stem Cells treated the first patients in an FDA-approved clinical trial for stem cell treatment of knee osteoarthritis.
October 17, 2019

Creative Medical Launching StemSpine Stem Cell Treatment in the U.S.

Creative Medical Technology will begin U.S. commercialization of StemSpine®, a regenerative stem cell procedure for the treatment of degenerative disc disease.
July 1, 2019

Celling Spine Acquires Assets of Link Spine

Celling Spine acquired all assets of Link Spine, and will develop spinal fusion hardware to complement its own orthobiologic product portfolio.
June 21, 2019

Royal Biologics Gains Funding

Royal Biologics, developer of products for regenerative medicine, received funding to support employee onboarding, operational growth, product development and acquisitions. 
December 11, 2018

DiscGenics Entering Clinical Trial in Japan for Disc Cell Therapy

DiscGenics received approval in Japan to advance into clinical studies of IDCT allogeneic injectible disc cell therapy for the treatment of lumbar degenerative disc disease.
November 6, 2018

Bone Therapeutics to End Phase III PREOB Study

The Data and Safety Monitoring Board recommended discontinuation of the Phase III hip osteonecrosis study of Bone Therapeutics' PREOB viscosupplement, following interim analysis of results.
August 2, 2018

RTI and Aziyo Partner on ViBone Cellular Matrix

RTI Surgical and Aziyo Biologics signed an agreement for RTI's exclusive U.S. distribution of ViBone® cellular bone matrix.
July 27, 2018

Stryker Posts 2Q18 Revenue Growth of 8% YoY

ORTHOWORLD estimates Stryker's 2Q18 orthopaedic revenue at US $1,747.8MM, +8.0% from 2Q17, and 1H18 revenue at $3,472.6MM, +7.5% vs. 1H17. Trauma and Extremities Joint Recon remain high performers, with Interventional and Tritanium products contributing to strong spine segment growth.

Member-Only Content

July 23, 2018

Bioventus to Divest BMP Development to Viscogliosi Brothers

Bioventus entered into a definitive agreement to divest its next-gen bone morphogenetic protein development program to Viscogliosi Brothers. The transaction is slated to close in 3Q18.
July 9, 2018

Lipogems Gains FDA Clearance for Adipose Tissue Transplant

Lipogems received FDA 510(k) clearance to market a Microfragmented Adipose Tissue Transplant system for use in orthopaedic and arthroscopic procedures. 
May 24, 2018

BONESUPPORT Signs Strategic U.S. Agreement with Collagen Matrix

BONESUPPORT entered into an agreement with Collagen Matrix on U.S. sales of bone graft substitute products through its own U.S. distribution network, beginning in 4Q18.
April 30, 2018

Biologica Technologies Presents Update on ProteiOS Growth Factor

Biologica Technologies is debuting initial clinical data from spinal applications using ProteiOS® growth factor. The product, which entered limited U.S. launch in 4Q17, is now available nationwide.
April 27, 2018

DiscGenics Treats First Patient in IDCT Trial

The first patient has been treated in DiscGenics' Phase I/II U.S. clinical trial of IDCT injection to treat degenerative disc disease.
March 7, 2018

Extremity Medical Affirms 2018 Product Launch Plans

Extremity Medical's 2018 product launches will include the Omni foot plating system, AlignX lateral plates for tibiotalar and tibiotalar-calcaneus fusion, Charcot-specific plates and the Freedom next-gen fixation system.
January 3, 2018

Zimmer Biomet Reports Positive Study Results with nSTRIDE APS in Knee OA

Zimmer Biomet announced positive results in a pilot study demonstrating safety and promising efficacy from use of the nSTRIDE® Autologous Protein Solution Kit to treat knee OA.
October 26, 2017

AMNIOX Introduces RESPINA Matrix for Microdiscectomy

AMNIOX Medical introduced RESPINA™ cryopreserved umbilical cord/amniotic membrane matrix, with application in microdiscectomy.
October 3, 2017

FDA Allows IND for DiscGenics’ Clinical Study

FDA accepted DiscGenics' Investigational New Drug Application for a clinical study of its cell therapy product candidate to treat degenerative disc disease.
September 26, 2017

DiscGenics Raises $14 Million for Injectable Cell Therapy

DiscGenics closed a US $14MM Series B financing. Funds will support regulatory approvals and manufacturing ramp-up for Phase III clinical and commercial production of its cell therapy for treatment of degenerative disc disease.
September 21, 2017

SpinalCyte Receives Australian Patent for Cartilage Repair

SpinalCyte was issued Australian Patent No. 2015202319, “Methods and Compositions for Repair of Cartilage Using an In Vivo Bioreactor.”
September 20, 2017

Bone Therapeutics ALLOB Phase I/IIA Delayed-Union Fracture Trial Update

Bone Therapeutics reports positive interim efficacy results and early conclusion of the Phase I/IIA study of ALLOB® allogeneic bone cell therapy in the treatment of delayed-union fractures.
September 6, 2017

Centric Medical Posts 112% Growth Within Foot & Ankle

Centric Medical announced record revenue growth of TARSA-LINK™ Stand-Alone Wedge Fixation, ROGUE™ Hammertoe Correction, OSTEO-LINK® 100% DBM and MARROW CELLUTION™ Bone Marrow Harvesting systems.

Member-Only Content

September 5, 2017

Medtronic Launches Study of INFUSE in PLF and TLIF

Medtronic launched a long-term global clinical study to collect prospective data on INFUSE® bone graft in posterolateral and transforaminal lumbar interbody fusion.
August 28, 2017

Regentis Biomaterials Receives CE Mark Approval for GelrinC Implant

Regentis Biomaterials received CE Mark approval for a GelrinC biodegradable implant based on denatured human fibrinogen for the treatment of articular knee cartilage defects.
August 28, 2017

Medtronic Posts FY1Q18 Revenue Growth

ORTHOWORLD estimates Medtronic's FY1Q18 revenue at US $728.0MM, +1.0% vs. FY1Q17. (Quarter ended 7/28/17) 

Member-Only Content

July 11, 2017

Carmell Therapeutics Closes $4MM Series B Funding

Carmell Therapeutics closed a US $4MM Series B financing. Funds will support Phase III clinical development of the company's Bone Healing Accelerant product.
June 21, 2017

Creative Medical Expands IP for its Cell-based Lower Back Pain Treatment

Creative Medical filed two patent applications regarding use of immune system cells to stimulate blood vessel formation for the treatment of lower back pain, and to support intradiscal stem cell administration to treat degenerative disc disease.
June 8, 2017

Creative Medical Seeks to Augment MSC Therapies for Low Back Pain

Creative Medical Technology filed a patent application covering synergy between intradiscal stem cell injections and stimulation of blood vessel formation around the spine.
June 8, 2017

ASC Biosciences to Receive $1.5MM Funding for Stem Cell Platform

ASC Biosciences partnered with Stem Cell Development Fund to receive US $1.5MM to support development and marketing of its Multipotent Adult Stem Cell platform.
May 8, 2017

Histogenics Update: Agreement with Japan PMDA on NeoCart Regulatory Path

Histogenics successfully completed consultations with Japan's PMDA regarding the regulatory path for NeoCart® autologous cell therapy for the treatment of knee cartilage defects. 
April 5, 2017

CellRight Technologies Launches Matrix OI Cortical Fibers

CellRight Technologies launched Matrix OI® Cortical Fibers, the latest in vivo verified osteoinductive matrix in its portfolio of regenerative human-derived osteobiologics.
March 9, 2017

Recruitment Status for ALLOB Delayed-Union Study

Bone Therapeutics completed recruitment of 16 patients in the Phase I/IIA delayed-union fracture study of ALLOB® allogeneic cell therapy product.
February 13, 2017

DePuy Synthes Launches ViviGen Formable Cellular Bone Matrix

DePuy Synthes and LifeNet launched ViviGen Formable™ Cellular Bone Matrix, next-gen allograft to support bone formation during spinal fusion.
January 12, 2017

Orthocell Collaborates with Johnson & Johnson Innovation

Orthocell entered into a research collaboration agreement with DePuy Synthes Products for the Ortho-ATI® stem cell treatment for tendon and ligament regeneration. 
December 9, 2016

Three-Month Interim Safety Data from Phase I Clinical Trial of AlloJoin

Three-month safety data from a Phase I clinical trial in China for Cellular Biomedicine's AlloJoin™ off-the-shelf allogeneic stem cell therapy in the treatment of knee osteoarthritis demonstrated a safety and tolerability profile of AlloJoin in the three doses tested, with adverse events similar to that of earlier autologous trials. The trial is slated for completion in 3Q17.
September 19, 2016

OSTEOGROW Research Update

OSTEOGROW, an EU-funded collaborative research project, is investigating a new bone regeneration therapy based on autologous blood + BMP-6 for use in applications requiring partial bone replacement, without the need for secondary interventions. 
July 25, 2016

MiMedx Planning U.S. Launch for Ambient Temperature Version of OrthoFlo

MiMedx is planning a U.S. launch for a next-generation lyophilized version of OrthoFlo, its amniotic fluid-based allograft for use in in orthopaedic and sports-medicine applications.  
June 27, 2016

Cytori Cell Therapy Receives Limited Approval in Japan

Cytori Therapeutics announced approval for Cytori Cell Therapy™ under the Japanese Act on the Safety of Regenerative Medicine. 
May 17, 2016

Novastep and Vivex Biomedical to Launch bioSTART Biologics

Novastep signed an agreement with Vivex Biomedical to launch bioSTART® Tissue Repair products, offering amniotic membranes and liquid to support foot and ankle procedures in the U.S.
February 17, 2016

ALLOB Phase IIA Spinal Fusion Trial Update

Bone Therapeutics has treated 12 patients in the ALLOB® Phase IIA spinal fusion trial, and reports no safety concerns.
February 2, 2016

Bone Therapeutics Extends Collaboration with Kasios

Bone Therapeutics extended its collaboration with Kasios to combine ALLOB® bone cell therapy with a 3D-printed synthetic cage intended to support the spinal fusion process.
January 11, 2016

MiMedx to Acquire Stability Biologics

MiMedx signed a definitive agreement to acquire Stability Biologics for US $10MM in cash and stock. Stability Biologics provides human tissue products for the surgical, spine and orthopaedic industries. The transaction is expected to close in early 1Q16.
January 5, 2016

Bone Therapeutics Granted Additional EUR 2MM in Funding

Bone Therapeutics was granted an additional 2MM (~US $2.15MM) in non-dilutive funding, bringing the total non-dilutive funding received within 2015 to 5MM.